Promising combo tackles tough breast cancer
NCT ID NCT02734290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took part. The goal was to see how many patients could finish treatment without serious side effects and whether their tumors shrank.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Providence Cancer Center
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- New PET tracer could sharpen detection of aggressive breast cancer